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Impact of immune microenvironment in prognosis of solid tumors has been extensively studied in the last few years. Speciﬁcally
in colorectal carcinoma, increased knowledge of the immune events around these tumors and their relation with clinical outcomes
have led to consider immune microenvironment as one of the most important prognostic factors in this disease. In this review
we will summarize and update the current knowledge with respect to this intriguing and complex new hallmark of cancer, paying
special attention to inﬁltration by T-inﬁltrating lymphocytes and their subtypes in colorectal cancer, as well as its eventual clinical
translation in terms of long-term prognosis. Finally, we suggest some possible investigational approaches based on combinatorial
strategies to trigger and boost immune reaction against tumor cells.
1.Introduction
The term immunity derives from the Latin word “immuni-
tas”, referred to the exemption of Roman senators in legal
procedures while holding their public oﬃce. In time, this
term has won many other meanings; in the Medical ﬁeld it is
employedtodescribethereactionofanorganismtowardsthe
aggression caused by external pathogens, initially infectious
agents. More recently, antigens derived from neoplastic
processes have been reported as responsible for triggering
immune responses. Most solid tumors induce an immune
response in the host, conﬁrmed by histopathological studies.
In this sense, tissue aﬀected by colorectal cancer is invaded
by immune cells from the host, suggesting that the amount
of lymphocytes may play a prognostic role with a potential
impact upon patient’s survival [1].
In Europe, 376.000 new cases of colorectal cancer are
diagnosedeachyear,withmortalitycloseto203.700patients.
It is one of the most frequent cancers worldwide, in both
genders [2, 3], and in most developed countries; as a resultof
screeninganddiagnostictechniquesandadvancesintheﬁeld
ofsurgeryandradio-chemotherapy,survivalhassigniﬁcantly
increased in the last decades. Most tumors aﬀecting the
colorectal area are adenocarcinoma-like which in most
cases are well or moderately diﬀerentiated. If colorectal
neoplasias invade through the muscularis mucosa into the
submucosa, local host reactions take place in cancer tissue
and proinﬂammatory cells accumulate along the margins
of the tumor, creating an immune microenvironment and
triggering an immune response targeted towards the tumor
[4].
2. Tumor Immune Microenvironment:
Immune-SurveillanceandTumor-Inﬁltrating
Lymphocytes (TILs)
In normal conditions, the immune system is an eﬀective
“gate-keeper” against cancer. Antitumor activity of the
immune system is initially mediated by innate immunity,2 Clinical and Developmental Immunology
mainly with eﬀector cells such as Natural Killer (NK)
cells, neutrophils, and macrophages. Subsequently, adaptive
immunitymechanismsareactivated.Thisresponseisspeciﬁc
and generates memory cells, mainly B and T-cells which
encompass the humoral and cellular immunity [1].
Cancer development can be explained, at least in part,
bythesuccessoftheimmunosuppressiveescapemechanisms
displayed by the tumor against the host’s immune response
[5]. This scenario is an area of great interest in the research
of tumor microenvironment, with evidence supporting the
hypothesis that a potent and eﬀective immune reaction
against certain tumor antigens (epitopes) may overcome
escapemechanisms,leadingtotheeliminationandcontrolof
the cancer [5]. The aforementioned evidence led to Hanahan
and Weinberg, among others, to postulate recentlyavoidance
of immune-surveillance as a new hallmark of cancer [6]. In
this sense, cancer cells may escape the innate and immune
host responses mainly by two mechanisms: selection of non-
immunogenic tumor cell variants (immunoselection) or by
active suppression of the immune response (immunosubver-
sion) [5, 6].
Tumor-inﬁltrating lymphocytes (TILs) are located in the
inﬂammatory inﬁltrates in tumor islets and in the peritu-
moral stroma of solid tumors [7]. TILs include cytotoxic
T-lymphocytes (CD8), NK cells, and helper T-lymphocytes
(CD4). Among the latter, there is a subpopulation of cells
known as regulatory T-cells (Tregs), formerly suppressor T-
cells,mainactorsinsuppressing andcontrollingtheimmune
response [8]. Whereas Treg cells carry out a physiological
role in the prevention of autoimmune events in the host
to avoid a disproportionate response to self antigens, in
the case of malignant neoplasias their presence seems
more related to immunosuppressive mechanisms preventing
immunomediated tumor destruction [9]. The relationship
between CD8/NK and Treg cells in the tumor-peritumor
microenvironment oﬀers an explanation to the ﬁnal eﬀect of
a triggered immune response with an eﬀective response or
an immunosuppressive eﬀect resulting in tolerance-anergy
[10].
3 .T h eI m m un eS y n ap s e s :R o l eo f
the Antigen 4 Associated to Cytotoxic
T Lymphocytes(CTLA-4)
The immune system is a homeostatic system with self-
regulating mechanisms that prevent excessive and harmful
responses towards the organism that lead to the destruction
of normal and healthy cells [1]. One of the key control
points in this immune response relies in the HLA-antigen
complex recognition by T-cell receptors. This interaction
is very complex and involves a series of ligands, such as
CD40, a surface molecule that appears early in activated
T-cells [7]. This ligand is essential in the generation of
antibodies by T-cell induced B lymphocytes as well as in the
activation of antigen presenting cells (APCs) which trigger
cellular immune responses. The interaction between CD40
ligand and receptor on B-cells and APC upregulates the
expression of two surface proteins, CD80 and CD86. When
these interact with CD28 on T-cells (immune synapses), T-
cells are activated [7]. However, interactions with antigen 4
associated to cytotoxic T lymphocytes (CTLA-4) on T-cells
leadtoastatusofanergyorimmunetolerance.OnceCTLA-4
(CD152) is generated, immune synapses are mobilized 2-3
days after T-cells are activated, binding to T-cell receptors
(TCRs) CD80 and CD86 [11]( Figure 1). CD80 and CD86
preferentially bind to CTLA-4, leading to a decrease in
IL-2 production, thus, in activated T-cells. A temporary
delay in CLTA-4 appearance on T-cell surface in the im-
mune synapses may trigger RCT and CD28-induced LT
activation and expansion, enhancing the immune response
[7, 12].
The blockade of CTLA-4 interaction with its ligands can
result in an augmentation of antigen speciﬁc T-cell responses
[13], and several studies have demonstrated that CTLA-
4 blockade can enhance immunity to tumors [14, 15]. It
has been reported that antibodies against CTLA-4 (anti-
CTLA-4) induce proliferation of TCR-stimulated T eﬀector
cells and abrogate Treg suppressive activity by enhancing
IL-2 and IFNγ release in response to polyclonal or tumor
antigen stimulation [16]. Curiously, anti-CTLA-4 does not
reduce the amount of Tregs, what suggests that anti-CTLA-4
mediates immune responses by direct activation of T eﬀector
cells and not by depleting Tregs [16].
There exist 2 CTLA-4 blocking antibodies for use in
humans that have been most widely tested in patients
with metastatic melanoma [17]. Recently, Ipilimumab has
gained FDA approval for clinical use in metastatic melanoma
patients after demonstrating beneﬁts in overall survival [18].
Clinical research of anti-CTLA-4 in other solid neoplasms
is scarse until now. However, a better understanding of the
mechanism of action of anti-CTLA-4, along with its use in
thecontextofcombinatorialstrategies,mayenabletoexplore
the eventual eﬃcacy of these molecules in nonmelanoma
tumors, including colorectal cancer [19].
4. PrognosticValue of Tumor-Inﬁltrating
Lymphocytes (TILs)and TheirSubtypes
in Colorectal Cancer
Microscopically, lymphocytes are observed as small cells
responding to classical hematoxylin-eosin stains and clearly
diﬀerent from other white cells such as plasmatic cells,
neutrophils, eosinophils, macrophages, and masT-cells. In a
study published in 1987 by Jass et al. [20], they reported
the possibility that lymphocytes inﬁltrate of the invasive
margins of rectal cancer could be an independent prognostic
factor for survival, advocating for a new prognostic tool
to calculate the risk of this disease. Ropponen et al. [21]
conﬁrmed the prognostic value of TILs in colorectal cancer,
quantifying them in the tumor stroma and along the invasive
margins of the tumor. They subdivided them into four
groups according to their histological grade and proved
that TILs inﬁltration was a predictive factor for disease-
free and overall survival. An inverse correlation was also
observed between the presence of TIL and tumor stage; thus
in advanced stages of the disease (Dukes stages C and D),Clinical and Developmental Immunology 3
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Figure 1: (1) CTLA-4 is a negative regulator of T-cell activation. (2) Conventional T-cells are activated by engagement of MHC and B7.
(3) Upon activation, T-cells express CTLA-4 on the cells surface and the union of CTLA-4 with B7 inhibits T-cell activation. (4) Antibody
blockade of CTLA-4 produces the liberation of CD28 which could engage with B7 with the best activation of T-cells.
TILs were less numerous than in early stages (Dukes stages A
and B) [21].
Follicular and paracortical hyperplasia in local lymphatic
nodes are also an important prognostic factor in colorectal
cancer. Phil et al. [22] proved in their study that immune
response observed in local lymphatic tissue might exert an
inﬂuence on survival. This study is particularly important
as it establishes a correlation between the immune response
observed in the tumor layer and in the ﬁrst lymphatic
settlement. Both immune responses are directly related;
hence immature dendritic cells migrate from the primary
tumor location to the local lymphatic node for maturation
and conversion to T-cell antigen presenting cells [22].
In most colorectal tumors, tumoral tissue is inﬁltrated
by a scarce number of lymphocytes and only along the
margins of the tumor the highest density of lymphocytes and
other inﬂammatory cells is observed. Proinﬂammatory cells
such as neutrophils and macrophages usually appear with
lymphocytes. The latter are usually CD4+ or CD8+ T-cells
while B-cells are generally observed in lymphoid follicles [1].
The speciﬁc TILs composition has a crucial role in
clinical evolution of colorectal cancer. Many research groups
have focused their eﬀort on analyzing the eventual relation
between T eﬀector cells and regulatory T-cells inﬁltrates and
clinical outcomes. Intraepithelial lymphocytes are mainly
CD8 and their number is consistently correlated with higher
disease-freesurvivalrates,asprovedinseveralstudies[4,23].
On the contrary, studies that analyze Tregs inﬁltration report
conﬂicting results [24].
4.1. Regulatory T-cells. Treg population represents roughly
the 10% of CD4 T-cells and speciﬁcally expresses the
forkheadboxP3transcriptionfactor(FOXP3)[25,26]which
confers them suppressive properties upon eﬀector T-cells
[27, 28]. Increased numbers of FOXP3-inﬁltrating tumor
cell nests have been demonstrated in several neoplasms,
and this event is generally associated with unfavourable
clinical outcomes. However, there are tumors where Treg
inﬁltration seems to play a diﬀerent role with protective
antineoplastic eﬀects. This is the case of some lympho-
proliferative syndromes, especially Hodgkin’s disease and
follicular lymphoma [29], and probably (but less clear) in
colorectal and head and neck carcinomas [30]. Regarding
colorectal cancer, Salama et al. [31] after analyzing 967
surgical specimens detected that a high density of Tregs
in tumor tissue was associated with better survival, being
the only immune biomarker independently associated with
overall survival in the multivariate analysis. In the same
way, Correale et al. [32] reported a better outcome in
advanced colorectal cancer treated with chemo or chemo-
immunotherapy if previously there was an intense Tregs
inﬁltration in primary tumors. Two other recent and large4 Clinical and Developmental Immunology
studies reported similar results, with favourable prognosis in
populations with high FOXP3 T-cell inﬁltration, at least in
the univariate analysis [33, 34].
Ladoire et al. revised in depth this issue and pretended
to give a plausible biological explanation based on the
diﬀerent eﬀects of Tregs populations, depending on the
diverse and speciﬁc microenvironment composition of the
tumors [30]. In this sense, they underscore that colorectal
carcinomas grow in a “septic microenvironment” where
many gastrointestinal bacteria reside and can be translocated
across the mucosal surface, inducing proinﬂammatory and
proangiogeniceﬀects,thatfavourthetumoralgrowth.Inthis
context,Tregsmaysuppresstheimmunereactioninducedby
these microorganisms and thus counteract their protumori-
genic eﬀects. This is an interesting and attractive hypothesis
which may explain the improved outcomes associated with
Treg inﬁltration in some neoplastic diseases (hematologic
and solid tumors) that have a tight relation with infectious
processes.
Although most of the studies advocate for the beneﬁcial
eﬀectsofTreginﬁltrationincolorectalcancer(Table 1),there
existotherworksthatcouldnotfullyconﬁrmedtheseresults.
Sinicrope [35] reported no signiﬁcant relation between Tregs
andprognosisandobservedthatalowepithelialCD3+/Tregs
ratio was associated with shorter disease-free survival. In
addition, Camus et al. [36] did not ﬁnd Tregs inﬁltration
as a reliable marker of good prognosis. Therefore, to date
there exist some conﬂicting results regarding clinical results
and accumulation of FOXP3 Tregs in specimens of colorectal
cancer and more data are needed to deﬁnitely elucidate and
establish their role in this disease.
4.2. Cytotoxic T CD8+ Cells. In relation to Tregs, results
regarding CD8+ inﬁltration in colorectal cancer are more
robust and concordant suggesting strong antitumoral eﬀects
and a positive eﬀect on patient survival [24]( Table 2).
Diederichsen et al. [37] showed throughout ﬂow cytometry
that a low CD4/CD8 ratio is an independent prognostic
factor for a better survival. The immunosuppressive role
of CD4+, CD25+, and FOXP3+ regulatory T-cells is also
elucidated [37].
In 2006, Galon et al. published in Science [39]a
very relevant study with clinical-pathological transcendence.
Genomic analyses were conducted on 75 cases of colorectal
carcinomainstagesItoIIIand415caseswithtissuemicroar-
rays, observing that tumors with lower rates of recurrence
had higher density of immune cells (TCD3, TCD8, memory-
TCD45RO, and granzyme B) in the analyzed regions in
comparison to recurrent tumors. This study shows that
adaptive immunity, expressed by Th1, is inversely propor-
tional to tumor recurrence; thus patients with increased Th1
gene expression present a better prognosis. Furthermore,
the centre and margins of the tumor were analyzed ﬁnding
that,inpatientswithoutrecurrence,immunecelldensitywas
higher in both areas. In patients with low density of total
lymphocytes TCD3 and memory lymphocytes (CD45RO+)
presented a worse prognosis, similar to those with distant
metastasis (stage IV). Patients were stratiﬁed according to
the UICC-TNM classiﬁcation, observing that an intense
immune response in situ was related to a favourable
prognosis despite local extension of the tumor and nodal
locoregional inﬁltration [39]. The authors ﬁnally advocate
for a redeﬁnition of the diagnostic and histopathological
approaches of these tumors as long as immune cell type,
density, and location in colorectal carcinoma proved to be
a superior prognostic factor and independent from classical
prognostic factors in this neoplasia (stage according to the
UICC-TNM classiﬁcation and nodal inﬁltration). However
it is important to notice that it is not possible to absolutely
discard an unbalanced selection of the cases due to a higher
number of tumors carrying DNA microsatellite instability
(MSI) in this study.
Multiple analyses clearly point out that the impact on
survival of CD8+ lymphocytes in colon cancer is more
o b v i o u sw i t hl o n g e rf o l l o w - u pp e r i o d s[ 42]. Moreover,
in follow-up studies conducted on patients with high or
low levels of CD8, survival curves during the ﬁrst two
years are very similar, further separating [24]. Chiba et al.
[38] proposed the hypothesis that the presence of CD8+
T-cells in tumor tissue could trigger an immunosurveillance
status in the organism, avoiding the development of distant
metastasis. Pag` es et al. [40] proved that early metastasis
development was associated with a poor immune response
in tumor tissue. This group demonstrated in 490 patients
of colorectal cancer that those patients with a high density
of CD45RO+ cells had better prognosis in terms of disease
free and overall survival compared with patients with a low
density of these memory cells. Tumors without signs of
early metastatic invasion had increased inﬁltrates of immune
cells, particularly CD8+ T-cells [40]. Furthermore, Pag` es
et al. [43] reported in 2009 another study in which they
classiﬁed 602 early-stage colorectal cancers (stage I and II)
into diﬀerent prognostic groups depending on the density
of CD45RO+ and CD8+ cells in two tumor regions (center
and invasive margin). Immune classiﬁcation was found to
be an independent prognostic factor in multivariate analysis
(P<0.0001), revealing recurrence rates of 4,8% versus
75% in high versus low CD8+ and CD45RO+ inﬁltration,
respectively [43]. Similarly, Mlecnik et al. [44] studied the
intratumoral immune inﬁltrates in a broader population
of stage I to IV colorectal cancers, measuring again the
lymphocyte inﬁltrates in the center and the invasive margin
of 599 specimens. They used the same immune score of their
previous study, deﬁning ﬁve patient groups (Im0, Im1, Im2,
Im3, Im4). Patients with low densities of CD45RO and CD8
in both tumor regions were classiﬁed Im0, and the rest of
groups were classiﬁed depending upon the density in every
tumor region up to the group of four high densities (Im4).
In this population, disease free survival and overall survival
was far better in the Im3 and Im4 groups, and multivariate
analysis conﬁrmed the advantage of the immune score (HR
0,64; P<0,001) compared with the classical TNM staging
[44].
4.3. DNA Microsatellite Instability. Another issue worthy
of consideration is the well-recognized better prognosis of
patients with colorectal cancer in the context of Lynch’s
syndrome [41]. In this sense, DNA microsatellite instabilityClinical and Developmental Immunology 5
Table 1: Studies of tumor-inﬁltrating immune cells (Tregs) and prognosis in colorectal carcinoma.
Study n Immune cells Findings: correlation with prognosis
Salama et al. [31] 967 CD8+, CD45RO+, and FOXP3+
tumor-inﬁltrating
Positive correlation for T-regs in tumor, negative in
normal mucosa
Correale et al. [32]5 7CD4+, CD8+, and FOXP3+ T-cells in
stroma adjacent to neoplastic glands Positive correlation for T-regs
Sinicrope et al. [35] 160 CD4+, CD8+, CD25+, and FOXP3+
T-cells
Negative correlation for T-regs. Positive correlation for
CD3+ T-cells
Frey et al. [33] 1420 FOXP3+ T-cells Positive correlation for FOXP3+ T-cells
Nosho et al. [34] 768 CD3+, CD8+, CD45RO+, and FOXP3+
T-cells
Positive correlation for CD8+, CD45RO+, and
FOXP3+ T-cells.
Table 2: Studies of tumor-inﬁltrating immune cells (Cytotoxic T CD8+ cells and CD45RO+) and prognosis in colorectal carcinoma.
Study n Immune cells Findings: correlation with prognosis
Naito et al. [4] 131 CD8+ and GrB+ tumor-inﬁltrating cells. Positive correlation for CD8+ T-cells
Jass et al. [20] 104 Tumor-inﬁltrating S-100+, HLA class
II+, CD208+, CD1a+ dendritic cells. Negative correlation for dendritic cells
Chiba et al. [38] 371 CD8+ T-cells within cancer cell nests Positive correlation for CD8+ T-cells
Galon et al. [39] 490
CD3+, CD8+, GrB+, and CD45RO+
lymphoid inﬁltrates in tumors/invasive
margin
Positive correlation for CD8+ and CD45RO+ T-cell
Pag` es et al. [40] 490
CD3+, CD8+, GrB+, and CD45RO+
lymphoid inﬁltrates in tumors/invasive
margin
Positive correlation for CD45RO+ T-cells
Camus et al. [36] 142
CD3+, CD5+, CD8+, CCR+, CD1a+,
Ki67+, CD68+, FOXP3+, and
cytoDEATH+ tumor-inﬁltrating cells
Positive correlation for CD8+ and CD45RO+ T-cells
Guidoboni et al.
[41] 109 CD3+, CD8+, and GrB+
tumor-inﬁltrating cells Positive correlation for CD8+ T-cells
Menon et al. [23]9 3 CD4+, CD8+, CD56+, and CD57+
intraepithelial cells. Positive correlation for CD8+ and CD57+ cells
Diederichsen et al.
[37] 41 CD3+, CD8+, and CD4+
tumor-inﬁltrating cells Positive for CD8+ T-cells, negative for CD4+ T-cells
Ogino et al. [42] 843 Lymphocytes on top of tumor cells Positive correlation for lymphocytes
Ropponen et al.
[21] 276 Lymphocytic inﬁltration in the center
and periphery of tumors Positive correlation for lymphocytes
is frequently observed in these hereditary nonpolyposic
colorectal cancers and by contrast is relatively uncommon
in sporadic colorectal tumors. Usually, tumor epithelium in
caseswithmicrosatelliteinstabilityisinﬁltratedbyCD3+and
CD8+ lymphocytes, probably resulting from an increased
immunologic reconnaissance of mutated proteins on the
epithelial surface [45]. Several studies have revealed that
microsatellite instability can be associated with a greater
T-cell inﬁltration in tumor tissue [41, 45–47], and hence
there has been postulated the hypothesis that this fact might
be on the basis of the better clinical outcomes associated
withthissubgroupofhereditarycolorectalcancers.Although
this is a plausible explanation, other further prospective
studies focusing on histopathologic ﬁndings in patients with
hereditary nonpoliposic colorectal carcinomas might clarify
this question.
4.4. Antigen Presenting Cells (APCs). Along with TILs,
antigen presenting cells (APCs) are another components
of adaptive immune system worthy of consideration, and
among them dendritic cells (DC) are retained as the most
potent antigen presenting cells. At present there are numer-
ous studies investigating their role in order to use them
in active immunotherapy (vaccines). In colorectal cancer,
dendritic cells are found along the invasive margins of the
tumor once they have developed completely in lymphoid
follicles [48]. The prognostic value of these cells is very
important. Dadabayev et al. [49] published that HLA-II cells
are distributed in the tumor stroma and that in cases with
high density of HLA-II cells, survival was lower; this may be
due to the fact that HLA-II cells in those cases are immature
as mature cells are scarce in tumor regions. Moreover, over-
expressed intercellular adhesion molecule ICAM-1 in tumor6 Clinical and Developmental Immunology
stroma ﬁbroblasts could interfere in dendritic cell functions
[50]. It is important to remind that tumor reactive T-cells are
often anergic because of inappropriate antigen exposure or
owed to self recognition; so DCs concourse seems essential
to trigger immune-mediated antitumor responses with the
ability to generate eﬀector and memory T-cells.
5. Immune Effects of Chemotherapy in
Colorectal Carcinoma
Colorectal cancer represents a wide group of heterogenic
diseases with diﬀerent clinical behaviours and response to
antineoplastic treatments. Nowadays, the main option in
advanced disease remains chemotherapy or biochemother-
apy. Recently, several studies have revealed that these treat-
ments seem to have a relevant impact on the surrounding
stroma and microenvironment [51]. Diﬀerent cytotoxic
drugs destroy tumor cells inducing a type of immunogenic
apoptosis, a process of cell death characterized by the
activation of caspases and exposure of phosphatidilserine
residuesintheouterleaﬂetofthecell[52],andrecentstudies
suggest that this kind of tumoral destruction may improve
cancer cell recognition by the immune system [53, 54].
Apoptosis or programmed cell death has been tradi-
tionally considered as immunologically “bland” or non-
immunogenic. However, this theoretical assumption has not
been conﬁrmed in basic and translational research. Rather, it
seems that apoptosis is a heterogeneous process that under
some circumstances may lead to immunogenic eﬀects [55–
57], and this ﬁnding is critical to understand better the
antineoplastic mechanism of action of some, if not most,
chemotherapies.
Oxaliplatin is one of the drugs of choice in advanced
colorectal cancer and is included in most of the ﬁrst line
chemotherapy schedules. The group of L. Zitvogel at the
Institut Gustave Roussy have studied extensively the immu-
nogenic death of cancer cells induced by chemotherapy, and
with respect to oxaliplatin they have demonstrated that it
may promote apoptosis in cancer cells via immunogenic
eﬀects through two main mechanisms [58, 59].
(1) EarlyApoptoticPhase:Calreticulin(CRT).Oxaliplatin
induces translocation of the intracytoplasmic protein
calreticulin to the cell surface, inducing the apoptotic
cell antigen presentation to dendritic cells and stimu-
lating speciﬁc antitumor T-cell responses [58, 59].
(2) Late Apoptotic Phase: High Mobility Group Box 1
(HMGB1). Another immunogenic determinant of
cell death is the proinﬂammatory factor HMGB1.
HMGB1 is a nuclear protein that is released after
necrotic cell death and, as recently reported, from
dyingcellsduringlatestageapoptosis.Afterdeathcell
induced by oxaliplatin, HMGB1 may be released in
the stroma and act as a neoantigen representing an
immunogenic endogenous “danger signal”, and thus
initiating an inﬂammatory response through binding
Toll-Like Receptor 4 (TLR4) on DC [59].
Therefore, immunogenic tumor cell death mediated by
chemotherapeutics like oxaliplatin is a multistep process
characterized by a temporal sequence of events (Figure 2)
including early translocation of calreticulin to the cell
surface, and thereafter interaction of CRT with multiple
receptors on DC with apoptotic bodies phagocytosis, release
and exposure of heat shock proteins, and late release
of HMGB1 (60). HMGB1 is able to bind to the TLR4
receptor on DC, which allows tumor-derived antigens to be
processed and presented along with MHC and costimulatory
molecules on the surface of DC [53, 60]. These mechanisms
altogether serve to trigger DC-mediated speciﬁc antitumor
response,whichmaybeenhancedbytheuseofcostimulatory
molecules like GM-CSF or interleukins [7, 61].
Therefore, in contrast with the previous theoretical
assumptions, chemotherapeutics like oxaliplatin can induce
a highly potent immune response by increasing neoantigen
threshold and presentation via antigen presenting cells, with
enhancement of T-cell response and generation of memory
T-cells [55, 57]. This new paradigm may serve to consider
chemotherapeutics as less empirical and more speciﬁc drugs,
and thus it is tempting to speculate that systemic treatments
in colorectal cancer might be customized taking into account
their potential eﬀects on tumoral microenvironment. In
this sense, there is an interesting ﬁeld of clinical research
to discover that may combine classical CT agents with
immunogeniceﬀectswithboostingcytokines(GM-CSF,IL2)
and new immunogenic molecules like monoclonal antibod-
ies anti-CTLA4 and CD40 agonists. These combinatorial
strategies may eventually sustain immunogenic eﬀect of
tumoral cell death, enhancing antigen recognition and thus
increasing the eﬀector and memory cells speciﬁc activity.
Regarding this, biomarkers of immune activity should be of
the greatest interest, in order to serve as proof of principle
of eﬃcacy with an earlier detection of the eventual beneﬁts
of oncological treatments in patients. In this sense, changes
detected during CT treatments in blood samples, especially
in immunophenotype, Tregs amount, and TCD8/Tregs ratio,
may represent interesting biomarkers to analyze and validate
in the future.
6. Conclusions
Scientiﬁc evidence supporting the importance of the
immune response in neoplastic diseases is growing. In
colorectal carcinoma, many studies endorse the prognostic
value of TILs inﬁltration density, depending on the speciﬁc
subtype of lymphocytes present. Thus, higher densities of
eﬀector TCD8 and NK cells in tumor islets and peritumoral
tissue seem to be associated with better long-term survival
rates.
Despite active research in this ﬁeld is ongoing and
there remain many issues still unsolved, available data
support the realization of a systematic histopathological
study of the tumor microenvironment along with the
classicalpathologicalstudiesincolorectalcancer.Inaddition,
immunemicroenvironmentmayrepresentanewoncological
target from a therapeutic perspective, giving rise to a new
promising chance of clinical research to our patients.Clinical and Developmental Immunology 7
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Figure 2: Early Apoptotic Phase: Calreticulin (CRT). oxaliplatin induces translocation of the intracytoplasmic protein calreticulin to the cell
surface, inducing the apoptotic cell antigen presentation to dendritic cells and stimulating speciﬁc antitumor T-cell responses.
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